T. Rowe Price Investment Management’s Maze Therapeutics MAZE Stock Holding History

T. Rowe Price Investment Management’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77.7M	Buy	+2,603,682	New	+$68.2M	0.05%	316

Other funds holding MAZE

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

T. Rowe Price Investment Management's MAZE Position: Q2 2026 in Review

T. Rowe Price Investment Management opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 2,603,682 shares worth $77.7M. The stake represents 0.05% of the portfolio and ranks #316 among its holdings.

118 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

T. Rowe Price Investment Management held 2,603,682 shares of Maze Therapeutics worth $77.7M as of Q2 2026.
Maze Therapeutics was a new T. Rowe Price Investment Management position in Q2 2026.
Maze Therapeutics made up 0.05% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #316 holding.
118 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.